Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine ... - Stock Titan
Shuttle Pharmaceuticals expands Phase 2 trial for Ropidoxuridine, a radiation sensitizer for glioblastoma, adding two sites to total four out of six planned. Targeting IDH wild-type, methylation negative patients, the trial aims to improve outcomes for this aggressive brain cancer. The study will enroll 40 patients initially, with an additional 14 to achieve statistical significance, expected to complete in 18-24 months.
Related Clinical Trials
Reference News
Shuttle Pharmaceuticals expands Phase 2 trial for Ropidoxuridine, a radiation sensitizer for glioblastoma, adding two sites to total four out of six planned. Targeting IDH wild-type, methylation negative patients, the trial aims to improve outcomes for this aggressive brain cancer. The study will enroll 40 patients initially, with an additional 14 to achieve statistical significance, expected to complete in 18-24 months.